Prefer to read in print? Subscribe for free here
If you would like to feature in the next issue of Pf Magazine, contact us here
Latest articles
Samsung Bioepis announces three-year follow-up data for biosimilar ONTRUZANT® (trastuzumab)
Samsung Bioepis announces three-year follow-up data for biosimilar ONTRUZANT® (trastuzumab) in early or locally advanced HER2-positive breast cancer. Samsung Bioepis has announced the findings of...
Servier & Harvard researchers collaborate to develop therapeutics
Servier has entered into a collaborative study with Harvard University researchers to explore a new avenue for the treatment of type 2 diabetes and...
2019 HSJ Partnership Awards winners
The 2019 HSJ Partnership Awards winners have been announced and they showcased effective partnership working within the NHS. With more than 700 NHS partners and...
Popular articles
Nurofen launches a 24 hour ibuprofen pain relief patch
Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen. Despite body pain being among the most commonly...
The future of genomics and precision medicine
How is the use of genomics data enhancing our medical understanding and what does this mean for the future of precision medicine? Genomics is one of...
Market Access in practice: do you have a strategy?
This article is a little old... but if you're interested in Market Access we have plenty of new content: July 2018 Market Access Special Edition...
Kate Lancaster will be the new RCOG Chief Executive
Kate Lancaster, the Director of Strategy at East and North Hertfordshire NHS Trust will be the new RCOG Chief Executive. The Royal College of Obstetricians...
UK launch of Jorveza announced for the treatment of EoE
Dr Falk Pharma UK announces the UK launch of Jorveza, the first globally licensed drug approved for the treatment of the immune mediated, chronic...